Jacob Robbins
Jacob Robbins (September 1, 1922 – May 12, 2008) was an American
thyroxine is only active when not bound to protein, and performed long-term research on the incidence of thyroid cancer caused by radiation in survivors of nuclear fallout
.
Biography
Robbins was born in 1922 in
Cornell Medical College in 1947.[1] He began working at Memorial Sloan Kettering Cancer Center in 1948 before moving to the National Institutes of Health in Bethesda, Maryland, in 1954 as an investigator. At NIH, he was chief of the Clinical Endocrinology Branch (part of the National Institute of Diabetes and Digestive and Kidney Diseases) from 1963 to 1991.[2][3]
Robbins worked alongside
radioactive iodine by the thyroid, for people living near nuclear power stations.[3] His other research topics included the effectiveness of iodine-131 therapy in certain types of thyroid cancer, the use of triiodothyronine (T3) prior to iodine-131 therapy, the relationship between thyroid-stimulating hormone (TSH) and thyroglobulin, the use of lithium to increase iodine-131 uptake, and the safety of weekly dosing of thyroxine replacement compared with daily dosing.[2]
Robbins served as editor-in-chief of NIH Clinical Center on May 12, 2008.[4]
References
- ^ a b c Vecchio, Giancarlo; Beckers, Christian. "Jacob Robbins (1922-2008)". European Thyroid Association. Retrieved July 12, 2020.
- ^ .
- ^ a b c Pearce, Jeremy (June 2, 2008). "Jacob Robbins, 85, Thyroid Researcher, Is Dead". The New York Times. Retrieved July 12, 2020.
- ^ a b c d Holley, Joe (May 16, 2008). "Jacob Robbins; NIH Scientist Known for Thyroid Research". The Washington Post. Retrieved July 12, 2020.
| International | |
|---|---|
| National | |
